• 1. Mixing of peptides and electrophilic traps gives rise to potent, broad-spectrum proteasome inhibitors
  Martijn Verdoes,Bogdan I. Florea,Wouter A. van der Linden,Didier Renou,Adrianus M. C. H. van den Nieuwendijk,Gijs A. van der Marel,Herman S. Overkleeft Org. Biomol. Chem. 2007 5 1416
• 2. Sonogashira and “Click” reactions for the N-terminal and side-chain functionalization of peptides with [Mn(CO)3(tpm)]+-based CO releasing molecules (tpm = tris(pyrazolyl)methane)
  Hendrik Pfeiffer,Alfonso Rojas,Johanna Niesel,Ulrich Schatzschneider Dalton Trans. 2009 4292
• 3. Steps towards sustainable solid phase peptide synthesis: use and recovery of N-octyl pyrrolidone
  Giulia Martelli,Paolo Cantelmi,Alessandra Tolomelli,Dario Corbisiero,Alexia Mattellone,Antonio Ricci,Tommaso Fantoni,Walter Cabri,Federica Vacondio,Francesca Ferlenghi,Marco Mor,Lucia Ferrazzano Green Chem. 2021 23 4095
• 4. Steps towards sustainable solid phase peptide synthesis: use and recovery of N-octyl pyrrolidone
  Giulia Martelli,Paolo Cantelmi,Alessandra Tolomelli,Dario Corbisiero,Alexia Mattellone,Antonio Ricci,Tommaso Fantoni,Walter Cabri,Federica Vacondio,Francesca Ferlenghi,Marco Mor,Lucia Ferrazzano Green Chem. 2021 23 4095
• 5. The complex-formation behaviour of His residues in the fifth Cu2+ binding site of human prion protein: a close look
  Maurizio Remelli,Daniela Valensin,Dimitri Bacco,Ewa Gralka,Remo Guerrini,Caterina Migliorini,Henryk Kozlowski New J. Chem. 2009 33 2300

• Solvents and Organic Chemicals Organic Compounds Benzenoids Fluorenes Fluorenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Fluorenes
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Professional Introduction to Fmoc-Thr(tBu)-OH (CAS No. 71989-35-0)

Fmoc-Thr(tBu)-OH, chemically known as N-(tert-butoxycarbonyl)-L-threonine, is a crucial intermediate in the field of peptide synthesis. This compound, identified by its CAS number 71989-35-0, plays a pivotal role in the production of various therapeutic peptides and biologics. Its unique structural properties make it an indispensable tool for researchers and pharmaceutical companies worldwide.

The structure of Fmoc-Thr(tBu)-OH consists of a threonine backbone modified with an N-(tert-butoxycarbonyl) group at the amino terminus and a hydroxyl group at the carboxyl terminus. The N-Boc (tert-butoxycarbonyl) group provides stability during peptide coupling reactions, while the hydroxyl group at the C-terminal allows for further functionalization. This dual functionality makes it an ideal building block for constructing complex peptide sequences.

In recent years, advancements in solid-phase peptide synthesis (SPPS) have significantly increased the demand for high-quality intermediates like Fmoc-Thr(tBu)-OH. SPPS is a widely used method for synthesizing peptides due to its efficiency and scalability. The use of Fmoc (fluorenylmethyloxycarbonyl) protected amino acids ensures high yields and purity, which are critical for pharmaceutical applications.

One of the most notable applications of Fmoc-Thr(tBu)-OH is in the synthesis of bioactive peptides. These peptides have garnered significant attention in therapeutic research due to their ability to modulate various biological processes. For instance, research has shown that certain peptidomimetics derived from threonine-based scaffolds exhibit potent anti-inflammatory and antimicrobial properties. The stability provided by the N-Boc group ensures that these peptides remain intact during synthetic processes, preserving their biological activity.

Recent studies have also highlighted the role of threonine derivatives in drug development. Threonine, being a non-polar amino acid with a hydroxyl group, offers versatility in designing peptidomimetics that can interact with biological targets. The tert-butoxycarbonyl protection on Fmoc-Thr(tBu)-OH enhances its compatibility with various coupling reagents, facilitating the construction of intricate peptide structures.

The pharmaceutical industry has leveraged these properties to develop novel therapeutic agents. For example, peptidomimetics targeting enzyme inhibition have shown promise in treating chronic diseases such as cancer and diabetes. The use of intermediates like Fmoc-Thr(tBu)-OH has enabled researchers to create highly specific and potent inhibitors with minimal side effects.

In addition to therapeutic applications, Fmoc-Thr(tBu)-OH is also utilized in academic research for exploring new biochemical pathways and developing diagnostic tools. Its role in constructing complex peptide libraries has been instrumental in understanding protein-protein interactions and identifying potential drug targets.

The synthesis of Fmoc-Thr(tBu)-OH involves multiple steps, each requiring precise control to ensure high yield and purity. Modern synthetic methodologies have improved the efficiency of these processes, making it more accessible for large-scale production. Techniques such as automated peptide synthesis machines have further streamlined the process, reducing human error and increasing reproducibility.

The quality of Fmoc-Thr(tBu)-OH is critical for successful peptide synthesis. Impurities or incorrect protection/deprotection steps can lead to low yields or non-specific reactions, compromising the final product's integrity. Therefore, stringent quality control measures are implemented during production to ensure consistency and reliability.

The future prospects of threonine-based intermediates like Fmoc-Thr(tBu)-OH are promising. As research continues to uncover new applications in drug development and biotechnology, the demand for high-quality intermediates will likely increase. Innovations in synthetic chemistry and process optimization will further enhance the accessibility and efficiency of producing these valuable compounds.

In conclusion, Fmoc-Thr(tBu)-OH (CAS No. 71989-35-0) is a vital component in peptide synthesis with diverse applications in pharmaceuticals and academic research. Its unique structural features and stability make it an indispensable tool for constructing complex bioactive molecules. As advancements continue to emerge, this compound will undoubtedly play a significant role in shaping the future of biotechnology and drug development.

• 1155-64-2(H-Lys(Z)-OH)
• 1164-16-5(Z-Tyr-OH)
• 73731-37-0(Fmoc-Thr-OH)
• 1148-11-4(Carbobenzoxyproline)
• 405-39-0(Z-Lys(Z)-OH)
• 125238-99-5((2S)-4-{[(tert-butoxy)carbonyl]amino}-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)butanoic acid)
• 1145-80-8(N-Carboxybenzyl-L-serine)
• 1152-61-0(Z-Asp-OH)
• 1152-62-1(Z-Met-OH)
• 1155-62-0(N-Carbobenzoxy-L-glutamic acid)